盐酸多柔比星脂质体治疗晚期肝细胞癌的临床研究

目的探讨盐酸多柔比星脂质体治疗晚期肝细胞癌的临床疗效。方法选取2017年1月—2018年3月在东莞市人民医院接受治疗的93例晚期肝细胞癌患者,随机分成对照组46例和治疗组47例。两组患者均接受TACE治疗,对照组术中使用盐酸多柔比星注射液,治疗组使用盐酸多柔比星脂质体注射液,每日20mg/m2。两组患者均接受1次治疗。观察两组的临床疗效,比较两组治疗前后肿瘤最大直径、Child-Pugh评分和甲胎蛋白的变化情况。结果治疗后,对照组和治疗组的总有效率分别是54.35%、74.47%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者肿瘤最大直径、Child-Pugh评分、甲胎蛋白显著下降,同组治疗前后比较差异有统计学意义(P0.05);治疗后,治疗组肿瘤最大直径、Child-Pugh评分和甲胎蛋白显著低于对照组,两组比较差异具有统计学意义(P0.05)。对照组和治疗组的生存率分别是32.61%、42.55%,两组比较差异有统计学意义(P0.05)。结论脂质体多柔比星治疗肝细胞癌晚期临床效果明显,能够有效减少肿瘤直径、改善肝功能,降低甲胎蛋白水平,具有一定的临床推广应用价值。

Clinical study on doxorubicin hydrochloride liposome in treatment of advanced hepatocellular carcinoma

Objective To investigate the clinical of doxorubicin hydrochloride liposome in Treatment of advanced hepatocellular carcinoma. Methods 93 Patients with advanced hepatocellular carcinoma in Dongguan People''s Hospital from January 2017 to March 2018 were randomly divided into control (46 cases) and treatment (47 cases) groups. Patients in both groups received TACE treatment, the control group received Doxorubicin Hydrochloride Injection, and the treatment group received Doxorubicin Hydrochloride Liposome Injection, 20 mg/m² daily for 3 days. Patients in two groups were treated for 1 time treatment. After treatment, the clinical efficacy was evaluated, and the changes of tumor maximum diameter, Child-Pugh score, and alpha fetoprotein in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 54.35% and 74.47%, respectively, and there were differences between two groups (P<0.05). After treatment, alpha fetoprotein, tumor maximum diameter and Child-Pugh score in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, alpha fetoprotein, tumor maximum diameter and Child-Pugh score in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, the survival rate in the control and treatment groups were 32.61% and 42.55%, respectively, and there were differences between two groups (P<0.05). Conclusion Doxorubicin hydrochloride liposome has significant effect in treatment of advanced hepatocellular carcinoma, and can effectively reduce tumor diameter, and can improve liver function, reduce alpha-fetoprotein levels, which has a certain clinical application value